Literature DB >> 3905985

Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole.

S Shadomy, S C White, H P Yu, W E Dismukes.   

Abstract

Ketoconazole was tested in vitro in three different media against 69 isolates of pathogenic fungi by using a macro-broth dilution procedure. The dimorphic systemic pathogens were highly susceptible, with most isolates of Blastomyces dermatitidis and Histoplasma capsulatum being inhibited and killed by concentrations less than or equal to 0.39 micrograms of ketoconazole/ml. Most isolates of Coccidioides immitis were also inhibited or killed by 0.39 micrograms of ketoconazole/ml; however, several were not killed by 100 micrograms/ml. Isolates of Cryptococcus neoformans and Sporothrix schenckii appeared to be less susceptible, with many isolates being resistant to less than or equal to 1.56 micrograms of ketoconazole/ml. There were 19 isolates of B. dermatitidis, C. immitis, and H. capsulatum recovered from 12 patients either during or following treatment with ketoconazole. Evidence for selection of secondary resistance to ketoconazole in these isolates was not observed. Results of these in vitro studies correlated poorly with the clinical responses to ketoconazole observed in the patients from whom the isolates were recovered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905985     DOI: 10.1093/infdis/152.6.1249

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia Dos Santos Lazéra; Bodo Wanke; Armando de Oliveira Schubach; Rodrigo de Almeida Paes; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 4.  Testing of organisms for susceptibility to triazoles: is it justified?

Authors:  G S Kobayashi; E D Spitzer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

Review 5.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 6.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 7.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

8.  Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.

Authors:  G V Doern; T A Tubert; K Chapin; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.